Other languages Kineta, Inc.

Equities

KA

US49461C1027

Market Closed - Nasdaq Other stock markets 04:30:01 2024-07-05 pm EDT			5-day change	1st Jan Change
0.6068 ^USD	+8.09%		+14.34%	-83.28%

May. 15	Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 08	Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial	Apr. 08
Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123	Mar. 12
Top Midday Decliners	Feb. 29
Kineta, Inc. Terminates Employment of Pauline Kenny as General Counsel and Secretary	Feb. 29
Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO	Feb. 29
Kineta, Inc. Announces Restructuring and Workforce Reduction	Feb. 29
Kineta Announces Exploration of Strategic Alternatives	Feb. 28
Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity	Jan. 17
Kineta, Inc. Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer?s 38th Annual Meeting	Nov. 06
Kineta, Inc. Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Advanced Solid Tumors	23-10-17
Sector Update: Health Care Stocks Advancing Late Afternoon	23-10-04
Sector Update: Health Care Stocks Lower Wednesday Afternoon	23-10-04
Kineta Prices $3 Million Registered Direct Offering of Common Stock; Shares Down Pre-Bell	23-10-04
Kineta, Inc. Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 Vista-101 Clinical Trial	23-10-03
Kineta Says It Is Set to Receive $5 Million Milestone Payment From Merck	23-06-29
Kineta, Inc. Announces Board Appointments	23-06-28
Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Top Premarket Decliners	23-04-28
Kineta, Inc. Unveils New Vista Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update At AACR Annual Meeting 2023	23-04-17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Kineta, Inc.

Equities

KA

US49461C1027

Other languages

Filters